The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling pathway has selective toxicity to malignant cells. The TRAIL receptors DR4 and DR5 are expressed at low levels in human umbilical cord blood cells (3-15%) and are upregulated by incubation with the cognate ligand, triggering apoptosis in 70-80% of receptor-positive cells (Po0.001). Apoptosis is not induced in hematopoietic progenitors, as determined from sustained severe combined immunodeficiency reconstituting potential and clonogenic activity. Furthermore, elimination of dead cells after incubation with TRAIL for 72 h results in a threefold enrichment in myeloid progenitors. Exposure to TRAIL in semisolid cultures showed synergistic activity of DR4 and granulocyte/macrophage colony-stimulating factor in recruiting lineage-negative (lin À ) and CD34 þ progenitors and in promoting the formation of large colonies. In murine bone marrow, B30% of lin À cells express TRAIL-R2 (the only murine receptor), and the receptor is upregulated after transplantation in cycling and differentiating donor cells that home to the host marrow. However, this receptor is almost ubiquitously expressed in the most primitive (lin
Introduction
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor (TNF) superfamily that participates in homeostatic regulation of cell death and activation. 1 Although it is expressed in many tissues under physiological conditions, TRAIL is not toxic to resting parenchymal cells and selectively kills malignant cells, 2-4 a differential sensitivity of neoplastic cells to TRAIL-induced apoptosis that can be used for therapeutic purposes. [5] [6] [7] For example, induced expression of TRAIL in CD34 þ cells 8, 9 and mesenchymal stromal cells 10, 11 was successfully applied to target tumor cells and induced their selective death in vitro and in vivo. In both cases, overexpression of TRAIL did not significantly affect the differentiation capacity of mesenchymal stromal cells into multiple lineages in vitro, 11 and the hematopoietic function of progenitors was preserved in vivo. 8 Although the intracellular signaling pathways associated with TRAIL receptor activation have been described in detail, [12] [13] [14] [15] [16] the role of TRAIL under physiological, pathological and stress conditions is not completely understood.
As other members of the TNF superfamily, TRAIL participates in the development and regulation of the immunohematopoietic system. [2] [3] [4] The ligand and its receptors are expressed at low levels in human hematopoietic progenitors under steady-state conditions; therefore, these cells are largely unaffected by this signaling pathway. [17] [18] [19] Among the known five TRAIL receptors, DR4 (TRAIL-R1) and DR5 (TRAIL-R2) are associated with transduction of apoptotic signals in humans, 16 whereas mice express only TRAIL-R2. 20, 21 Although mRNA encoding TRAIL receptors DR4 and DR5 is frequently detected in CD34 þ progenitors, these cells were insensitive to apoptosis 22, 23 even in the presence of low doses of doxorubicin. 24 Consistently, infusion of soluble TRAIL into rodents was not associated with gross abnormalities in hematopoiesis, 25, 26 and TRAIL neither induced nor impaired the clonogenic activity of human hematopoietic progenitors in vitro. 22, 23 These data argue that TRAIL is not a significant factor in proximal stages of hematopoietic cell differentiation. Nevertheless, administration of recombinant human TRAIL to nonhuman primates resulted in mild anemia, 27 and this pathway is considered to contribute to deficient erythropoiesis in myelodysplastic syndromes. 23, 28, 29 Therefore, TRAIL may serve as a negative regulator of expanding clones in the distal stages of differentiation of all hematopoietic lineages. 13, [17] [18] [19] 30, 31 As umbilical cord blood (UCB) becomes an important source of hematopoietic progenitors for transplantation, we evaluated the effect of TRAIL in proximal stages of their activity. We recently showed that the Fas/Fas-ligand interaction transduces trophic signals in early stages of hematopoietic cell engraftment, 32 because the most primitive progenitors are insensitive to Fas-mediated apoptosis. 33 This is the apparent reason for upregulation of Fas expression in donor cells soon after homing to the host bone marrow (BM). In this study, we evaluated the signaling activity of TRAIL receptors in UCB cells and found that TRAIL is involved in complex apoptotic and tropic signaling in proximal stages of hematopoietic progenitor function. Following these observations, we monitored the dynamics of murine TRAIL receptor-2 after transplantation, this being the only known murine receptor for TRAIL that corresponds to human DR5. 20, 21 We found that signaling by the murine receptor is trophic in nature.
Materials and methods

Animal preparation and transplantation
The mice used in this study were C57BL/6J (B6, H2K ) and NOD.CB17-Prkdcscid/J (non-obese diabetic severe combined immunodeficiency (NOD.SCID)), purchased from Jackson Laboratories (Bar Harbor, ME, USA). Mice were housed in a barrier facility and all procedures were approved by the Institutional Animal Care Committee. Wild-type recipients were routinely conditioned 1 day before transplantation by total body irradiation at 850 rad using an X-ray irradiator (RadSource 2000; RadSource, Suwanee, GA, USA) at a rate of 106 rad/min. Notably, X-ray irradiation is different from g-irradiation in myeloablative dose and toxicity. NOD.SCID mice were conditioned with two daily doses of 25 mg/g busulfan, administered 2 days before cell transplantation. Cells suspended in 0.2 ml of phosphate-buffered saline (Biological Industries, Kibutz Beit Haemek, Israel) were infused into the lateral tail vein.
Cell isolation, characterization and staining
In mice, whole BM cells (BMCs) were harvested from femurs and tibia and placed in M199 (Beit Haemek, Israel) in aseptic conditions, as previously described. 32, 33 The lineage
(lin À/low ) subset was immunomagnetically depleted with saturating amounts of hybridoma-derived rat anti-mouse monoclonal antibodies (mAb) specific for CD5, B220, Mac-1, Gr-1 and TER-119, NK1.1 purchased from eBioscience (San Diego, CA, USA). Antibody-coated cells were incubated with sheep-anti-rat IgG conjugated to M-450 magnetic beads (Dynal Inc, Lake Success, NY, USA) and lineage-positive (lin þ ) cells were retained by exposure to a magnetic field. The efficiency of the lin À cell separation procedure was reassessed by flow cytometry using a cocktail of fluorescein-isothyocyanate-labeled mAb against the lineage markers (eBioscience; Pharmingen, Erembodegem, Belgium; and IQ Products, Groningen, The Netherlands).
Umbilical cord blood was obtained from healthy donors pending informed consent according to institutional guidelines. UCB samples that were harvested before placental delivery with citrate-phosphate-dextrose adenine-1 were diluted twofold in phosphate-buffered saline containing 0.5% human serum albumin and 2 mM ethylenediaminetetraacetic acid, and collected by centrifugation using lymphocyte separation medium (1.077-1.080 g/ml; MP Biomedicals, Illkirch, France). Mononuclear cells (MNCs) were washed twice, and the lin À/low subset was immunomagnetically isolated using the Human Lineage Cell Depletion Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). The efficiency of lin À cell separation was reassessed as detailed above using a cocktail of phycoerythrin-labeled antibodies.
For staining with an intracellular dye, cells were incubated for 7 min with 2.5 mM of 5-(and 6-)carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, Eugene, OR, USA), washed, resuspended and counted.
Flow cytometry
Measurements were taken with a Vantage SE flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Peripheral murine blood and BMCs were layered over 1.5 ml of lymphocyte separation medium at room temperature (Cedarlane, Burlington, ON, Canada), collected from the buffy coat and stained with primary-labeled mAb. In murine experiments, donor chimerism in syngeneic transplants was determined with mAb against minor antigens CD45.1 (clone A20; eBioscience) and CD45.2 (clone 104; eBioscience). Murine cells were assayed for progenitor markers c-kit (CD117, clone 2B8; eBioscience) and Sca-1 (clone D7; eBioscience), and for expression of TRAIL-R2 (CD262, clone MD5-1; eBioscience).
Expression of TRAIL receptors in UCB cells was determined using mAb against TRAIL-R1 (clone 69036; R&D Systems, Minneapolis, MN, USA) and TRAIL-R2 (clone 71908). Human neuroblastoma SHEP-1 cells served as positive controls for TRAIL-R2. Engraftment of UCB cells in NOD.SCID xenochimeras was determined in the BM after 12 weeks using antibodies against murine CD45 (clone 30-F11; eBioscience) and human CD45 (clone ML2; IQ Products).
Cell death and apoptosis was determined in cells incubated with 5 mg/ml 7-aminoactinomycin-D (7-AAD, Sigma, St Louis, MO, USA) and Annexin-V (IQ products).
Apoptotic challenge
Murine BMCs and human UCB cells were incubated (5 Â 10 6 cells per ml) for variable times in a-MEM culture medium (Beit Haemek) supplemented with StemPro Nutrient Supplement (Stem Cell Technologies, Vancouver, BC, Canada), 2 mM L-glutamine and 50 mM 2b-mercaptoethanol purchased from PeproTech (Rocky Hill, NJ, USA). 32 Murine and human cells were challenged with various concentrations of soluble TRAIL (PeproTech) and evaluated for apoptotic activity in murine A20 and human Jurkat cells.
Colony-forming unit assays
Colony-forming unit (CFU) assays were performed in methylcellulose containing Iscove modified Dulbecco's medium (IMDM, Beit Haemek) supplemented with 2 mM L-glutamine. In murine assays, 3 Â 10 5 whole and 3 Â 10 4 lin À BMCs were plated in 1.2% methylcellulose containing 20% fetal calf serum, 20 ng/ml recombinant mouse stem cell factor , 10 ng/ml of recombinant mouse interleukin-3, 10 m/ml recombinant human erythropoietin and 5 ng/ml granulocyte/macrophage colonystimulating factor (GM-CSF) (recombinant mouse GM-CSF).
In UCB cell assays, 2.5 Â 10 3 MNCs per well and 10 3 CD34 þ or lin À cells per well were plated in 0.9% methylcellulose containing 30% fetal calf serum , 50 ng/ml stem cell factor, 10 ng/ml interleukin-3 and 10 ng/ml rhGM-CSF (PeproTech). TRAIL was supplemented at 200-1000 ng/ml in murine cell assays and 500-2000 ng/ml in human cell assays, with and without blocking anti-DR4 (clone 69036, R&D Systems) and anti-DR5 (clone 71908, R&D Systems) antibodies.
Statistical analysis
Data are presented as means ± standard deviations for each experimental protocol. Results in each experimental group were evaluated for reproducibility by linear regression of duplicate measurements. Differences between the experimental protocols were estimated with a post hoc Scheffe t-test and significance was considered at Po0.05.
Results
Expression of TRAIL receptors in human UCB cells
The dynamics of receptor-ligand interactions can be monitored in UCB cells without disrupting the close interaction between hematopoietic progenitors and stroma in the BM. Lin À and CD34 þ progenitors derived from fresh human UCB express relatively low levels of TRAIL receptors, predominantly DR4 (Po0.05 versus DR5 þ , Figure 1a ), with a disproportionately higher expression of DR4 over DR5 being most accentuated in mononuclear UCB cells (Po0.001). The low-level expression of DR5 was not a result of deficient antibody-mediated labeling, as SHEP-1 cells were effectively stained for this receptor. Incubation of UCB cells in liquid culture for 4 days resulted in a gradual increase in cell death to 40%, which was not significantly affected by exposure to a toxic concentration of 1.5 mg/ml TRAIL, as determined from apoptosis in Jurkat cells (Figure 1b) . The apparent insensitivity of UCB cells to TRAILinduced apoptosis corroborates previous observations. [17] [18] [19] 22 Apoptosis of lin À and CD34 þ UCB progenitors (B25%) was slightly lower than that observed in the heterogeneous MNC population after 3 days of liquid culture (Figure 1c ), whereas the highest sensitivity to apoptosis was apparent in myeloid cells (CD33 þ ) and B-lymphocytes (CD19 þ ). The low sensitivity of T cells (CD3 þ ) to apoptosis may be explained by their naive nature in UCB, 34 as opposed to the sensitivity of activated T cells to TRAIL-mediated apoptosis. 35 
Dynamic changes in TRAIL receptors during in vitro incubation
Although TRAIL had no apparent significant influence on UCB cell sensitivity to apoptosis, several parameters were modulated during incubation with the ligand for 72 h. An intriguing observation was a 50% decrease in DR4 expression during control incubation in medium, resulting in low levels of expression of both TRAIL receptors ( Figure 2a ). In contrast, TRAIL induced a twofold increase in the expression of DR4 and DR5 (Po0.05), in particular in CD33 þ cells, showing an upregulation of the cognate receptors as previously reported for Fas-ligand in murine BMCs. 32 Thus, UCB cells were apparently insensitive to TRAIL-induced apoptosis, despite expression of both receptors in 15% of the cells at the end of the incubation period. The changes in TRAIL receptor expression in culture might be caused either by differential sensitivity to apoptosis of receptor-positive cells, variations in proliferation rates or true modulation of receptor expression.
To assess these possibilities, cell death was assayed in reference to TRAIL receptor expression in liquid culture. Approximately 70% of DR4 þ and DR5 þ cells succumbed to apoptosis under control conditions of incubation in medium (Po0.001 versus MNCs), as well as during incubation with TRAIL, suggesting a higher sensitivity to spontaneous death of these cells in the absence of specific signaling (Figure 2b ). Thus, cells expressing TRAIL receptors were more sensitive to apoptosis in control culture, and the fraction of receptor-positive apoptotic cells was constant despite an upregulation of receptors triggered by the cognate ligand. These differential responses of subsets of receptor-positive cells to TRAIL had variable contributions to cell mortality: approximately 5% of DR4 þ and DR5 þ cells were apoptotic under control culture conditions (26±6% overall MNC death), whereas the DR4 þ and DR5
þ subsets corresponded to B10 and B14% of TRAIL in cord blood and murine hematopoietic progenitors K Mizrahi et al apoptotic cells, respectively, during exposure to TRAIL (33 ± 8% overall MNC death). Under these conditions, DR5
þ cells cycled faster than DR4 þ cells, irrespective of the presence of the cognate ligand (Figure 2c ), indicating that differential proliferation was not the primary cause for the observed variations in sensitivity to apoptosis. However, the faster cycling rates might be responsible for the apparent relative increase in DR5 as compared with DR4 on exposure to TRAIL. These data revealed that TRAIL induces expression of its cognate receptors, and modulates the pattern of apoptosis in culture because of sensitivity to apoptosis of cells responsive to the ligand.
Differential stimulation of progenitors by TRAIL
As TRAIL-mediated signaling is coupled to both apoptotic and nonapoptotic pathways, [12] [13] [14] [15] [16] its effects were further assessed in clonogenic assays of UCB-derived progenitors. This ligand showed an interesting effect on progenitor engagement to clonogenic activity: TRAIL suppressed CFU-GM activity in bulk UCB cells at low concentrations (0.25-1 mg/ml) and induced this activity at higher concentrations ( Figure 3a) . In contrast, dosedependent activation was observed in lin À and CD34 þ progenitors, starting at low concentrations. The decline in the activity of progenitors in bulk cell populations is attributed to the indirect suppressive effects of dead cells on clonogenic activity. 32 The constant presence of the ligand in cultures influenced two distinct events: recruitment of progenitors to perform clonogenic activity and regulation of colony size. The latter parameter was evaluated by analysis of the partition of large (450 cells) and small (30-50 cells) To determine the TRAIL receptor that is responsible for tropic signaling, cultures were performed in the presence of blocking antibodies to DR4 and DR5 (Figure 3c ). Inhibition of DR4 resulted in a slight decrease in the activation of clonogenic activity by TRAIL, whereas inhibition of DR5 resulted in increased clonogenic activity (Po0.01). Although there were minor differences in stimulation of whole BMCs and lin -progenitors, the activity of both subsets was increased by selective stimulation of DR4, the receptor that also presents more potent apoptotic activity. It is therefore an antagonistic mode of regulation of progenitor activity in which DR4 stimulates and DR5 has a mild inhibitory effect, which results in the overall stimulation of UCB progenitors by TRAIL.
Functional assessment of UCB cells exposed to TRAIL
In view of the variable effects of TRAIL on apoptosis and activity of UCB progenitors, we assessed the overall impact of this ligand in two functional assays. The activity of SCID-repopulating cells was evaluated after preincubation of UCB cells for 1-3 days with 1.5 mg/ml TRAIL before transplantation into immunocompromised mice (Figure 4a ). Within the wide distribution of the levels of xenogeneic chimerism of human cells from a single UCB unit, short-term incubation (24 h) with TRAIL did not impair SCID-repopulating cell activity, as previously reported. 23 Incubation for 3 days showed a modest decrease of 8±5% in the SCID-repopulating activity of UCB cells incubated with TRAIL, compared with control medium (n ¼ 4 individual UCB units). Evidently, prolonged exposure to TRAIL in culture has little effect on the SCID-repopulating cell activity of UCB cells, suggesting that progenitors survive these culture conditions. To better quantify the effect of TRAIL, cells incubated under the same conditions were assessed for CFU-GM activity (Figure 4b) . Culture of equal numbers of viable cells showed no significant difference after incubation for 1 and 3 days. Elimination of dead cells by centrifugation over ficoll showed a remarkable increase in colony-forming cell activity when equal numbers of viable cells were plated after incubation with TRAIL for 24 h (Po0.05) and 72 h (Po0.001). The threefold enrichment in clonogenic activity attained by incubation with TRAIL for 72 h is evidence that CFU-GM activity was spared and its fraction increased on removal of dead cells (Figure 4c) . Notably, enrichment of progenitors by incubation with TRAIL is different from the effect of the ligand when continuously present in clonogenic assays of naive UCB cells. These functional assays show that TRAIL does not induce apoptosis in progenitors responsible for reconstitution of SCID mice and enriches UCB progenitors by elimination of other cell subsets.
Expression of the TRAIL receptor in murine BM and grafted cells
Considering these data acquired on surrogate assays of human UCB cells, the impact of TRAIL was evaluated in a more physiological assay of murine BM transplants. Among the five known receptors for TRAIL in humans, 2-4 the dominant receptor identified in rodents corresponds to DR5 (TRAIL-R2). 20, 21 This receptor is expressed at relatively low levels in murine whole BMCs; however, it is detectable in 30±3.5% of lin À progenitors (Figure 5a ). These levels of expression exceed those of Fas and TNF receptors. 32 (Figure 5b ). This pattern of expression was similar to the previously reported upregulation of Fas in grafted BMCs, 33 and TRAIL-R2 was coexpressed with Fas in 85% of BM-homed donor cells, suggesting a coordinated upregulation of these receptors. In variance, residual host BMCs that survived irradiation and recovered thereafter showed a low-level expression of TRAIL-R2 (Figure 5b) , consistent with the polarized nature of Fas expression in donor and host-type cells coresiding in the BM after transplantation.
32,33 TRAIL-R2 was upregulated primarily in cycling cells (CFSE dim ), which comprise 25-30% of BM-homed cells 48 h after transplantation, and was expressed in a relatively small fraction of quiescent cells (CFSE bright , Figure 1c ). The early proliferating and quiescent/slow-cycling subsets of BM-homed donor cells are dissociated in their composition, with lin À cells consisting of 34±10 and 73±4% of these subsets, respectively (n ¼ 7). Consistently, TRAIL-R2 was upregulated primarily in the lin þ subset of BM-homed donor cells (Figure 1d It has been previously shown that overexpression of TRAIL in BMCs is not detrimental to the hematopoietic reconstituting potential of progenitors, 8 and a consistently direct administration of soluble TRAIL to mice had no toxic effects. 25, 26 Although TRAIL is not a significant molecular mediator of graft-versus-host disease, 36 selective expression of the receptor in donor cells might mediate rejection of the cell graft. To evaluate this possibility, cells were harvested from femurs at 2 and 4 days after transplantation and were exposed to TRAIL in vitro. This apoptotic challenge resulted in an insignificant increase in apoptosis (17±2.3%), as compared with medium (14±3%), and was not attenuated by incubation with TRAIL in conjunction with either Fas-ligand or TNF-a. Similarly, day þ 4 BM-homed cells were insensitive to TRAIL-mediated apoptosis, which seems to be an intrinsic insensitivity of primitive progenitors to receptor-mediated apoptosis. 32 We have also reported that Fas, the common executioner of apoptosis in the TNF superfamily, 1 transduces tropic signals to hematopoietic progenitors that promote hematopoietic cell engraftment. 33 Assessment of colony-forming cell activity in methylcellulose assays showed a mild but consistent inhibitory effect of TRAIL concentrations higher that 200 ng/ml on whole BMCs (Po0.001, Figure 6a ). In variance, the clonogenic activity of lin À progenitors increased by 50% (Po0.001). As shown above, B30% of these murine progenitors expressed the TRAIL receptor at culture onset. Specificity of the interaction between TRAIL and the cognate receptor was validated with a neutralizing antibody, which abolished the topic effect of TRAIL (Figure 6b ). According to these data, the TRAIL/TRAIL-R2 interaction evolves as another mechanism that promotes rather than inhibits donor cell function after transplantation.
Discussion
The TRAIL receptors evolve as a complex signaling mechanism that affects multiple hematopoietic cell functions. In general, our findings are consistent with previous reports showing that TRAIL does not negatively impact hematopoietic progenitors. 9, 10, [22] [23] [24] However, detailed analysis of the dynamics of cultured cells revealed a complex pattern of cognate receptor induction, differential proliferation and sensitivity to apoptosis of cells expressing DR4 and DR5. In this study, we report that TRAIL induces expression of its two receptors involved in apoptotic signaling, triggers death of nonprogenitor UCB cells in culture and imposes both suppressive and inductive effects on clonogenic activity. In murine BM transplantation, TRAIL evolves as a stimulatory factor that promotes hematopoietic reconstitution.
The contention that resting hematopoietic progenitors are not induced to apoptosis by TRAIL receptors [17] [18] [19] [22] [23] [24] best describes the preservation of the engraftment and reconstituting potential, as shown here and in previous studies. 23 Humanmouse xenochimerism was not impaired by preincubation with TRAIL, showing that SCID-repopulating cells were spared and not induced into apoptosis. Our findings that exposure of UCB cells to TRAIL for 3 days had no toxic consequences extend the Figure 4 Functional assessment of TRAIL-exposed UCB cells. (a) UCB cells were incubated for 24 and 72 h with and without 1.5 mg/ml TRAIL before infusion into busulfan-conditioned NOD.SCID mice. Engraftment was determined in the BM after 12 weeks using human-specific antibodies. Data are representative of four UCB units for each culture time, in which engraftment was measured in at least two recipients in the pretreated and control groups. (b) UCB cells were preincubated for 24 (n ¼ 4) and 72 h (n ¼ 4) with 1.5 mg/ml TRAIL, and equal numbers of viable cells were assayed in semisolid cultures in the presence of stem cell factor , interleukin-3 and GM-CSF, with and without centrifugation over ficoll. CFU activity is calculated for 10 3 cells at the onset of culture. (c) Enrichment was determined by normalization against clonogenic activity without removal of dead cells by ficoll (n ¼ 4).
TRAIL in cord blood and murine hematopoietic progenitors K Mizrahi et al previous observation of insensitivity of CD34 þ cells to shortterm (1 day) exposure to TRAIL before transplantation. 23 Although SCR cells generally relate to human reconstituting cells, their relationship to progenitors that provide short-term radioprotection and durable multilineage engraftment is uncertain. 37, 38 Survival of short-term reconstituting progenitors was evident from preservation of CFU-GM activity after exposure to TRAIL. When dead cells were removed, TRAIL in cord blood and murine hematopoietic progenitors K Mizrahi et al TRAIL-mediated signaling deviates toward tropism in the subset of apoptosis-insensitive cells inducing differentiation in conjunction with GM-CSF.
Selective sensitivity to apoptosis was unrecognized when heterogeneous populations of UCB cells were examined, with prevalent apoptotic death of B-lymphocytes and myeloid cells. However, apoptosis was attenuated by dynamic changes in TRAIL receptor expression in liquid culture, with the ligand inducing expression of DR4 and DR5 and triggering death in 70-80% of these receptor-positive cells. These data confirm the contention that DR4 is associated with apoptotic signaling, 3 and consistently its expression was accompanied by slower proliferation rates in the presence of the cognate ligand. TRAIL is best characterized in committed erythroid progenitors, in which it serves as a negative regulator: DR4 induces apoptosis and DR5 arrests differentiation by activation of extracellular signalregulated protein kinase and mitogen-activated protein kinase. 4, 19 In variance, TRAIL has been associated with increased maturation in the myeloid lineage. 39 The dosedependent increase in colony size is evidence that supplementation of exogenous TRAIL at saturating concentrations enhances the maturation of developing myeloid cells. As hematopoietic cells (in particular those of the myeloid lineage) secrete TRAIL in response to inflammatory cytokines, 40 this ligand may serve as an autocrine positive feedback mechanism activated in response to injury and/or changing cytokine composition in the environment. In addition, synergism with GM-CSF in recruitment of progenitors to clonogenic activity was observed in human UCB progenitors, with DR4 being the primary signaling mediator of tropism in human cells and DR5 showing a mild inhibitory effect. Consistently, the only murine receptor, analog to human DR5, assumes the inductive function of DR4 in human UCB cells. TRAIL therefore participates in all stages of myeloid cell differentiation, starting at the early stage of progenitor commitment and continuously supporting the growth of developing colonies.
The TRAIL receptors are associated with Fas-associated death domain-mediated recruitment of death domains, caspaseindependent transduction of apoptosis and concomitant activation of the nuclear factor-kB pathway, 16 which might correspond to modulation of both apoptotic and tropic signaling in UCB cells. These distinct effects were best characterized in isolated subsets of cells, whereas in bulk preparations of human UCB cells and murine BM, TRAIL indirectly affected the assays. For example, the clonogenic activity of bulk MNCs (human and murine) was suppressed at low concentrations of TRAIL, an inhibitory effect attributed to dead cells in the culture. 32 The dose-dependent increase in human colony-forming cell engagement to clonogenic activity induced by high concentrations of TRAIL is evidence that its stimulatory effect overrides the indirect inhibition associated with cell death. The threefold enrichment in clonogenic activity attained by preincubation with TRAIL was more pronounced than the 1.5-fold increase when TRAIL was constantly present in the semisolid medium, suggesting that some inhibitory cells might have been removed by this ligand. 32 It is therefore speculated that TRAIL specifically removes inhibitory cellular elements, resulting in a marked increase in clonogenic activity after exposure to this ligand before culture.
Within heterogeneous cell compartments and dynamic environments it is difficult to estimate the physiological role of this molecular interaction in hematopoietic homeostasis. Approximately 10% of human lin À progenitors express DR4, suggesting that a small fraction of fresh UCB cells is responsive to TRAIL-mediated signaling. However, in murine BM, B30% of lin À progenitors express TRAIL-R2, the only known receptor in rodents. 20, 21 Possibly, the differences between murine BMCs and human UCB cells reflect the differential behavior of these cell subsets rather than species-specific variations. UCB cells represent a more primitive subset of circulating progenitors, whereas BM cells live in close contact with and under the control of the marrow stroma. TRAIL has multiple implications in the function of marrow stroma, including endothelial cells, 3 bone 41 and mesenchyme, 42 and the elevated levels of receptor expression in hematopoietic cells suggest involvement of this molecular pair in cell-stroma interaction. A common pattern of upregulation of TRAIL receptors under stress conditions in murine BMCs (transplant) and human UCB cells (ex vivo incubation) renders them more responsive to this signaling pathway. Notably, expression was not induced only by injury factors released as a consequence of radiation of the marrow stroma; the murine receptor was also upregulated in donor cells that homed successfully to the BM of nonirradiated hosts, and expression was induced by interaction with the stroma. In addition, TRAIL receptors were endogenously upregulated in cultured UCB cells in the absence of inductive factors. These data exemplify different situations in which TRAIL receptors are induced by the cognate ligand, in response to culture and interaction with marrow stroma, with a significant number of hematopoietic cells becoming responsive to this signaling pathway.
Clonogenic assays attribute a primary trophic role to TRAIL signaling, which is consistent with the need to enhance progenitor activity under hypoplastic environments such as the irradiated BM. Upregulation of death receptors is not limited to transplantation, as similar dynamics have been observed on activation of murine hematopoiesis with 5-fluorouracil (PearlYafe M, unpublished data). A dose-dependent stimulatory effect of TRAIL in progenitors suggests participation of the ligand in correlating hematopoietic activity to the severity of injury. It is tempting to speculate that this is the reason for inhibition of erythropoiesis, [13] [14] [15] [16] while promoting the activity of colonyforming cells for other lineages. [2] [3] [4] [12] [13] [14] 30, 31, 39 This pattern of behavior of death receptors in hematopoietic progenitors is not unique to TRAIL in the mouse, and is shared by Fas 32, 33 and TNF receptors (Pearl-Yafe M, unpublished data). Importantly, topic signaling mediated by death receptors relies on the intrinsic insensitivity of primitive progenitors to apoptosis triggered by membranal receptors of the TNF superfamily. 33 In the context of transplantation, the findings presented here have several implications. First, donor cells can be indeed purged of residual neoplastic cells if the latter are sensitive to TRAIL-induced apoptosis. 24 Second, activation of short-term reconstituting cells, corresponding to committed progenitors that are active in clonogenic assays, might augment early UCB cell engraftment, which is one of the problems associated with the use of this rich source of progenitors. 43 Third, overexpression of TRAIL in UCB-derived progenitors seems to be safe and might be of benefit. TRAIL is important in the initiation of graft-versus-tumor reactivity, 36 and hematopoietic and mesenchymal progenitors can be used as vehicles that efficiently target neoplastic cells in vivo. [8] [9] [10] [11] Thus, in addition to the selective sensitivity of neoplastic cells to TRAIL, 2-4 its engraftment-promoting attributes suggest its usefulness as an immunotherapeutic adjuvant to chemotherapy. 24, 44 Furthermore, membrane-bound ligands of the TNF family, such as Fas-ligand, are effective in counterattacking graft rejection in addition to graft supportive functions. 45 Therefore, TRAIL evolves as a promising immunotherapeutic agent, particularly in emerging approaches, to induce graft-versus-tumor reactivity through nonlife-threatening transplantation under nonmyeloablative conditioning. [46] [47] [48] [49] TRAIL in cord blood and murine hematopoietic progenitors K Mizrahi et al
